Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation, symbol TWST, stands at the forefront of synthetic biology with an innovative approach to DNA synthesis. The company's core expertise lies in developing a proprietary semiconductor-based synthetic DNA manufacturing process. This process utilizes a unique 10,000-well silicon platform, markedly different from the traditional 96-well plastic plates. This advanced platform enables the production of synthetic biology tools, such as oligonucleotides, genes, pathways, chassis, and genomes, in a more efficient, cost-effective, and high-throughput manner.
The implications of Twist Bioscience's technology are profound, offering the potential to revolutionize various fields. By synthesizing DNA on silicon, the company overcomes existing production inefficiencies, ensuring rapid and high-quality DNA synthesis. This capability is crucial for accelerating developments in personalized medicine, sustainable chemical production, agricultural improvements, in vivo diagnostics, biodetection, and even data storage.
Based primarily in the United States, Twist Bioscience derives the majority of its revenue from its home market. The company's strategic partnerships and ongoing projects reflect its commitment to pioneering advancements in synthetic biology. Having positioned itself as a leader in the field, Twist Bioscience continues to support researchers and industries by providing high-quality synthetic DNA rapidly, enabling them to seize emerging opportunities.
For more information, please visit Twist Bioscience.
Twist Bioscience Corporation (Nasdaq: TWST) announced positive preclinical data for GLP-1R antibodies from its proprietary GPCR libraries, showing effective blood glucose control. The data, published in mAbs, highlight 13 high-affinity GLP-1R antibodies that could have multiple clinical uses, including treatment for Type-2 diabetes. Notably, the antibody TB59-2 demonstrated a two-day half-life, indicating potential for once-weekly administration. CEO Emily M. Leproust emphasized collaboration with various partners to optimize antibody discovery.
Twist Bioscience Corporation (Nasdaq: TWST) has announced the shipment of new synthetic RNA reference controls for SARS-CoV-2 variants B.1.351 and P.1, as well as controls for the B.1.1.7 variant in a stabilized format. These products aim to enhance global surveillance efforts amid increasing vaccination rates. The company continues to provide essential tools to identify and monitor COVID-19 mutations, demonstrating commitment to public health. Twist's synthetic controls, based on specific SARS-CoV-2 variants, are designed to cover the full viral genome and are verified for accuracy.
Twist Bioscience Corporation (NASDAQ: TWST) has partnered with Watchmaker Genomics to enhance research capabilities in high throughput sequencing applications. Their collaboration aims to facilitate innovations in oncology, inherited disease detection, and liquid biopsy assays. The first product will integrate Watchmaker's high-fidelity amplification technology into Twist's library preparation kits. Both companies focus on delivering exceptional products, optimizing workflows, and improving genomic studies quality through joint development initiatives.
Twist Bioscience Corporation (NASDAQ: TWST) has announced its participation in the virtual 2021 Advances in Genome Biology and Technology (AGBT) meeting scheduled for March 1-3, 2021. Key events include a workshop featuring customer presentations from Regeneron Genetics Center and HelioHealth, along with a poster presentation on Artificial Barcoded Libraries (ABLs) aimed at enhancing NGS sequencing. Twist's innovative DNA synthesis platform positions it at the forefront of synthetic biology, serving industries like healthcare and agriculture.
Twist Bioscience (NASDAQ: TWST) has launched the Twist NGS Methylation Detection System, an innovative tool for analyzing DNA methylation patterns. This system is designed for early cancer detection through blood tests, utilizing next-generation sequencing technology. Partnering with New England Biolabs, Twist's system overcomes challenges in traditional methylation detection by using EM-seq for sample preparation. Early access customer HelioHealth reports improved efficiency and accuracy in developing liquid biopsy tests for cancers. The system aims to enhance research capabilities and diagnostic accuracy in genomics.
Twist Bioscience Corporation (NASDAQ: TWST) announced a partnership with Berry Genomics, a leading next-generation sequencing (NGS) provider in China. This collaboration will integrate Twist’s NGS target enrichment and library preparation tools into Berry’s offerings, enhancing the capability to diagnose cancer and genetic diseases. The partnership emphasizes high-quality NGS panels and continuous development of diagnostic solutions. Dr. Emily M. Leproust, CEO of Twist, highlighted the importance of this collaboration for precision medicine in China.
Twist Bioscience Corporation (NASDAQ: TWST) has announced that CEO Emily Leproust, Ph.D., and CFO Jim Thorburn will present at several virtual investor conferences. The presentations include the SVB Leerink 10th Annual Global Healthcare Conference on February 26 at 11:20 a.m. ET, the Cowen 41st Annual Healthcare Conference on March 4 at 1:30 p.m. ET, and the Barclays Global Healthcare Conference on March 9 at 10:20 a.m. ET. These fireside chats will be webcast live and available for 30 days afterwards. Twist Bioscience is known for its innovative synthetic DNA technology.
Twist Bioscience (NASDAQ: TWST) and Victorian Clinical Genetic Services (VCGS) have collaborated to create a novel whole exome capture assay utilizing Next Generation Sequencing (NGS). This assay enhances diagnostics and carrier screening by enabling comprehensive analysis of clinically relevant regions with minimal gaps. VCGS, accredited for in vitro diagnostics, will utilize this advanced assay for patient management. Twist's Comprehensive Exome Assay covers over 99% of protein-coding genes, facilitating improved variant detection and customization capabilities, thus delivering high-quality, actionable genetic data.
Twist Bioscience (NASDAQ: TWST) reported strong financial results for Q1 FY2021, with total orders reaching $33.6 million, up from $24.8 million a year prior. Revenue increased to $28.2 million, compared to $17.2 million in Q1 FY2020. Although the net loss narrowed to $32.9 million (or $0.72 per share), up from $55.6 million (or $1.69 per share) year-over-year, the company strengthened its balance sheet with $324 million raised through an equity offering. Future growth is anticipated with the launch of new products and expansion of manufacturing capabilities.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
What does Twist Bioscience Corporation do?
How does Twist Bioscience's technology differ from traditional methods?
What are some applications of Twist Bioscience's synthetic DNA?
Where does Twist Bioscience generate most of its revenue?
How does Twist Bioscience contribute to personalized medicine?
What is the significance of using silicon in DNA synthesis?
Can Twist Bioscience's technology be used in agriculture?
What ongoing projects does Twist Bioscience have?
How does Twist Bioscience's platform support researchers?
Where can I find more information about Twist Bioscience?
